Dementia Clinical Trials

Find Dementia Clinical Trials Near You

Autophagy-Enhancers to Reduce Sleep Disturbances: A Combined Approach

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This clinical trial investigates the effects of spermidine supplementation on sleep quality and memory function in older adults with Mild Cognitive Impairment (MCI), a condition associated with an increased risk of developing dementia, particularly in patients with MCI due to Alzheimer's disease. Impaired sleep has been identified as a modifiable factor contributing to cognitive decline, and interventions targeting sleep architecture could offer therapeutic potential to prevent or slow down this decline. Spermidine is a naturally occurring polyamine found in foods such as wheat germ and soybeans. It induces autophagy, a cellular degradation and recycling process essential for neuronal maintenance and function. In animal studies, spermidine has been shown to improve memory performance, reduce neuroinflammation, and support mitochondrial health. Preliminary findings from human trials in individuals with subjective cognitive decline or MCI suggest potential cognitive benefits of spermidine, but results are not unequivocal, and the impact on sleep has not been systematically evaluated. In this randomized, double-blind, placebo-controlled trial, 76 participants aged 55 to 70 years with MCI will receive either spermidine (6 mg/day) or a placebo for 12 weeks. Sleep will be evaluated using overnight EEG in a controlled laboratory setting, focusing on measures such as slow-wave sleep and sleep spindle activity. Memory performance will be assessed before and after the intervention using standardized neuropsychological testing. Numerical skills will be tested at baseline only to compare MCI patients with healthy controls. Blood samples will be collected to quantify metabolic indicators, neurodegeneration-related biomarkers, and autophagy-associated proteins. A control group of 38 cognitively healthy individuals will undergo comparable sleep and cognitive assessments without receiving any supplementation. The primary objective of the study is to characterize the impact of spermidine on sleep-dependent memory consolidation and to identify associated biological changes relevant to aging and neurodegeneration. The results may inform the development of non-pharmacological strategies aimed at preserving cognitive function in individuals at risk for dementia.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 55
Maximum Age: 70
Healthy Volunteers: t
View:

• Men and women

• Written consent to participate in the study

• German at native speaker level

• Age between 55 and 70 years

• Mild cognitive impairment (MCI) operationalized as:

‣ A change in cognitive abilities reported by the patient, relatives or clinic staff (i.e. historical or observed evidence of deterioration over time)

⁃ Objective evidence of memory impairment (at least 1.0 Standard Deviation (SD) below the normal range on the Wechsler Logical Memory Scale (WMS-LM)); other cognitive domains may also be affected (i.e. amnestic MCI and amnestic + MCI)

⁃ Preservation of independence of functional abilities

⁃ No dementia

• Men and women

• Written consent to participate in the study

• German at native speaker level

• Age between 55 and 70 years

• Subjective cognitive disorders are denied

Locations
Other Locations
Germany
Department of Neurology, University Medicine Greifswald
RECRUITING
Greifswald
Contact Information
Primary
Agnes Flöel, Prof. Dr.
agnes.floeel@med.uni-greifswald.de
+49 (0)3834 86-6815
Backup
Silke M Wortha, Dr.
SilkeMaria.Wortha@med.uni-greifswald.de
+49 3834 86 - 6704
Time Frame
Start Date: 2025-10-28
Estimated Completion Date: 2029-05
Participants
Target number of participants: 76
Treatments
No_intervention: Healthy elderly controls
baseline comparison, healthy controls are not part of the intervention
Placebo_comparator: Dietary Placebo
Experimental: Dietary Supplement
Related Therapeutic Areas
Sponsors
Collaborators: Institute of Biology, Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin, Department of Experimental Neuroimmunology, University Medicine, Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald
Leads: University Medicine Greifswald

This content was sourced from clinicaltrials.gov

Similar Clinical Trials